Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its news flow reflects both its operating performance and corporate developments. Company announcements describe technologies that prioritize preservation and restoration of the patient’s own anatomy and leverage the natural healing response while minimizing long-term exposure to permanent synthetic materials.
News updates for TELA stock frequently include quarterly financial results, where the company reports revenue, gross profit, operating expenses, and net loss, along with commentary on demand for its OviTex and OviTex PRS reinforced tissue matrix products. These releases often discuss factors driving revenue, such as increased unit sales, new customers, international sales, and new product configurations, as well as changes in operating expenses and loss from operations.
Investors can also expect capital markets and financing news, including announcements of credit facilities, registered direct offerings of common stock and pre-funded warrants, and the issuance of warrants in connection with debt agreements. Such updates provide insight into TELA Bio’s liquidity, borrowing arrangements, and intended use of proceeds for sales and marketing, research and development, and other corporate purposes.
Another category of TELA Bio news involves corporate governance and leadership changes, such as appointments of new independent directors with experience in healthcare equity research and executive nursing leadership, as well as board resignations. The company also issues releases about participation in healthcare conferences and inducement grants of restricted stock units and stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
By following TELA Bio’s news feed, readers gain timely visibility into the company’s financial performance, product demand trends in soft-tissue reconstruction, capital-raising activities, and changes in board composition and employee equity incentives.
TELA Bio, Inc. (NASDAQ: TELA) announced the appointment of John Nosenzo, former Chief Commercial Officer at Bioventus Inc., to its board of directors, effective June 2, 2021. This change coincides with the departure of board member Adele Olivia, resulting in a board of seven directors, six of whom are independent. Nosenzo brings extensive healthcare marketing and sales experience, which could positively impact TELA's strategic direction. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to improve clinical outcomes.
TELA Bio, Inc. (NASDAQ: TELA) has appointed Marissa Conrad as Vice President of Clinical and Regulatory Affairs, effective May 24, 2021. With over 16 years of experience in R&D, clinical, and regulatory roles in the medtech industry, she will oversee clinical and regulatory strategies for TELA's current and future products. CEO Antony Koblish praised her as a valuable asset, highlighting her strong track record and leadership skills. TELA Bio aims to enhance soft tissue reconstruction solutions through its innovative products, such as OviTex®.
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company focused on innovative tissue reinforcement materials, will participate in two investor conferences. The management will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 8:00 AM EST. The Jefferies Virtual Healthcare Conference is scheduled for June 3, 2021, at 3:30 PM EST. Both presentations will be accessible via the company’s investor relations website. TELA Bio aims to enhance clinical outcomes in soft tissue reconstruction with its OviTex® products.
TELA Bio, Inc. (NASDAQ: TELA) has launched the BRAVO II study to evaluate the clinical performance of OviTex® Reinforced Tissue Matrices in robotic ventral hernia repairs. The first patient was enrolled at St. Luke's Hospital in Kansas. This study aims to enroll up to 100 subjects across seven US sites, focusing on early postoperative complications and long-term hernia recurrence. CEO Antony Koblish expressed commitment to enhancing surgical materials, while Dr. Geoffrey Slayden highlighted the advantages of using reinforced tissue matrices in robotic procedures.
TELA Bio, Inc. (Nasdaq: TELA) reported strong financial results for Q1 2021, achieving revenue of $5.9 million, a 58% increase from Q1 2020. Despite challenges from COVID-19, the company saw high utilization of its OviTex LPR product line, marking the highest volume quarter for these products. Gross profit remained stable at 59% of revenue. Operating expenses rose to $10.7 million, resulting in a net loss of $8.1 million for the quarter. For the full year, TELA maintains a revenue guidance of $27-30 million, reflecting a growth of 48-65% year-over-year.
TELA Bio, Inc. is set to report its first quarter financial results for the period ending March 31, 2021, on May 13, 2021. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio focuses on innovative tissue reinforcement materials designed for soft tissue reconstruction, aiming to offer effective biologic material repair solutions and improve clinical outcomes. The company is committed to addressing unmet needs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
TELA Bio reported fourth quarter revenue of $5.7 million, an increase of 17% year-over-year, and full-year revenue of $18.2 million, up 18% from 2019. Gross profit for Q4 was $3.7 million (65% margin), and $11.2 million (62% margin) for the full year. Operating expenses rose to $10.4 million in Q4 and $36.5 million annually, leading to net losses of $7.8 million and $28.8 million, respectively. For 2021, TELA projects revenue between $27.0 million and $30.0 million, indicating growth of 48% to 65%.
TELA Bio, a medical technology company, has reported encouraging findings from the 12-month analysis of its BRAVO study on OviTex Reinforced Tissue Matrix for ventral hernia treatment. Out of 76 patients, only two experienced a recurrence at the surgical site, while interim results at 24 months showed no recurrences among the 51 patients followed. The results demonstrate low postoperative complications, and the data have been submitted for journal publication. TELA anticipates completing the BRAVO trial this year, highlighting OviTex's potential in hernia repair.
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, will report its fourth quarter and full year 2020 financial results on March 24, 2021. The management team will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a corporate update. TELA specializes in innovative tissue reinforcement materials aimed at soft tissue reconstruction, particularly in hernia repair and abdominal wall reconstruction.
MALVERN, Pa., Feb. 4, 2021 - TELA Bio, a commercial-stage medical technology company, will participate in the BTIG Virtual MedTech Conference on February 18, 2021, at 4:30 PM EST. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to enhance patient outcomes while minimizing reliance on synthetic materials. TELA's key products include OviTex® and OviTex PRS Reinforced Tissue Matrix, designed for hernia repair and reconstructive surgeries. Interested parties may access the webcast via their [investor relations page](https://ir.telabio.com).